What is Cotadutide?

A GLP-1/glucagon dual agonist from AstraZeneca studied in diabetes, fatty liver and kidney disease; development stopped in 2023.

Cotadutide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

10 registered trials · 13 indexed papers · 13 human / 3 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

Mechanism (as described)

  • The glucagon part increases liver glycogen breakdown and energy use (Parker et al., 2023).

Evidence (as described)

  • A 54-week phase 2b trial in type 2 diabetes reported glucose, weight and liver improvements (Nahra et al., 2021); a kidney trial was also published (Selvarajah et al., 2024).

Status

Development discontinued.

Registered human trials (10)

TrialPhaseStatusYearEnrolled
A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy ParticipantsPhase 1terminated202331
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy SubjectsPhase 1completed202210
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisPhase 2completed202254
Chinese Multiple Dose Escalation (MDE) High Dose StudyPhase 1completed202216
Pharmacokinetics of Cotadutide in Participants With Hepatic ImpairmentPhase 1terminated202224
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusPhase 2completed2020248
Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes MelitusPhase 1completed202016
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.Phase 2completed201974
A Study Investigating the Pharmacokinetics of a Single Dose Administration of CotadutidePhase 1completed201936
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese ParticipantsPhase 1completed201851

Peer-reviewed studies (13)

PaperAuthorsJournalYearType
Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitusYu H et al.British journal of clinical pharmacology2025Randomized Controlled Trial
A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney diseaseSelvarajah V et al.Kidney international2024Randomized Controlled Trial
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With FibrosisShankar SS et al.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2024Randomized Controlled Trial
Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesityGolubic R et al.Diabetes, obesity & metabolism2024Randomized Controlled Trial
Characterisation of cotadutide's dual GLP-1/glucagon receptor agonistic effects on glycaemic control using an in vivo human glucose regulation quantitative systems pharmacology modelBosch R et al.British journal of pharmacology2024Randomized Controlled Trial
Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetesParker VER et al.Nature metabolism2023Randomized Controlled Trial
Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m(2) or higher: A phase I, randomized, double-blind, placebo-controlled studyAsano M et al.Diabetes, obesity & metabolism2023Randomized Controlled Trial
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney diseaseParker VER et al.Diabetes, obesity & metabolism2022Randomized Controlled Trial
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b StudyNahra R et al.Diabetes care2021Randomized Controlled Trial
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetesAsano M et al.Diabetes, obesity & metabolism2021Clinical Trial, Phase I
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon AgonistParker VER et al.The Journal of clinical endocrinology and metabolism2020Randomized Controlled Trial
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a studyAmbery P et al.Lancet (London, England)2018Randomized Controlled Trial
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 studyAmbery PD et al.British journal of clinical pharmacology2018Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Cotadutide?

A GLP-1/glucagon dual agonist from AstraZeneca studied in diabetes, fatty liver and kidney disease; development stopped in 2023.

How many registered human trials study Cotadutide?

The PeptideWhiz trial index lists 10 registered trials for Cotadutide, the most recent from 2023.

How much published research exists on Cotadutide?

The PeptideWhiz paper index links 13 PubMed papers to Cotadutide; by study type, 13 human and 3 animal studies.

Which conditions is Cotadutide researched for?

Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney).

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research